Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T in R/R CD19+ Aggressive Non-Hodgkin's Lymphoma
NCT04440436Phase 2Recruiting
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of IM19 in non-Hodgkin lymphoma (NHL), sponsored by Immunochina Pharmaceuticals. Started Jun 2020; status: recruiting.
02
Drugs
IM19
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04440436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440436.